Mozobil is approved by the FDA to be used in combination with another
agent (granulocyte‑colony stimulating factor (G-CSF) to
mobilize hematopoietic stem cells to the peripheral blood for collection
and subsequent autologous transplantation in patients living with
non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM).
Our passion is to improve access to medicines and provide support. Explore available resources, including Sanofi Patient Connection™.